Q-omics provides the consensus-scored TMEM191B profile across patient tissues and cancer cell-line models. TMEM191B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, TMEM191B is differentially expressed in 4, with the highest sampling consensus in BLCA. Additionally, TMEM191B RNA expression shows 11,572 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight STAD, BLCA, and ACC as cancer lineages where TMEM191B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM191B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM191B survival associations across molecular data types. TMEM191B RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM191B RNA expression–survival associations across cancer types. High TMEM191B expression shows unfavorable associations in UVM, ACC and SCLC, but favorable associations in STAD, ESCA and CHOL. The STAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify STAD as the clearest survival context for TMEM191B RNA expression.
This table summarizes TMEM191B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM191B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM191B shows higher tumor expression in BLCA, LIHC, BRCA and CHOL. The BLCA box plot shows higher TMEM191B RNA expression in tumor versus normal tissue (log2 FC = +0.540, t-test p = .026).
This table shows molecular features associated with TMEM191B in patient tissues and cancer cell lines. In patient samples, TMEM191B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM191B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE.
